U.S. Food and Drug Administration

Amgen Inc AMGN stock MariTide obesity drug pipeline September 3 2026

Amgen (NASDAQ:AMGN) Stock Rises 2.94% to $390.02 on September 3: MariTide Obesity Drug Pipeline and Q2 Beat Fuel Rally

Amgen Inc. surged 2.94% to $390.02 on September 3, 2026, one of the Dow Jones Industrial Average's top performers as investors priced in the company's expanding obesity drug pipeline and a second-quarter

September 4, 2026

Business·Health·News

Merck pharmaceutical drug manufacturing plant exterior

The Quarter Merck Lost $1.3 Billion – and Raised Its Revenue Outlook Anyway

Merck posted a GAAP net loss of $1.34 billion in Q2 2026, but the number was accounting, not collapse — a $5.7 billion one-time charge from the Terns acquisition masked revenue of

September 1, 2026

Business·News

Melatonin supplement bottles on a pharmacy shelf

The Sleep Supplement Millions Take Nightly May Carry a Hidden Heart Risk

A large analysis of more than 130,000 adults with insomnia found that long-term melatonin users faced a 90 percent higher hazard of heart failure over five years — a signal that researchers

August 31, 2026

Health·News

Signage for Sun Pharmaceutical Industries, India's largest drugmaker and the heaviest weight in the Nifty Pharma index

FDA Inspection Fears Drag Nifty Pharma Lower as Cipla and Sun Pharma Retreat

India's pharmaceutical sector closed August 31 on a cautious note, with the Nifty Pharma index shedding 186.40 points to settle at 22,614.70 as unresolved U.S. FDA inspection uncertainty weighed on drug stocks

August 31, 2026

Business·News

CAR T-cell therapy for rheumatoid arthritis treatment at Charité Berlin

CAR T-Cell Therapy Achieves Drug-Free Remission in Rheumatoid Arthritis, Trial Finds

A Phase 1 trial at Charité Berlin found a single CD19 CAR T-cell infusion achieved medication-free remission in three of six treatment-resistant rheumatoid arthritis patients, the first peer-reviewed evidence of its kind

August 30, 2026

Health·News